transformational targets. first and Thank truly XXXX, us as for year full Quoin's our publicly we morning, key a all you, company, successfully was of operational good a one Gordon, which delivered as traded was everyone. across
some almost from fundamental completed I'm moment the investors public contributing. on and brought approximately want a XXXX, with you inform previous in every take also begin offering again last year $X raise a of I in which the of to pleased review net for comment highlights of month last August I Before that proceeds new investor Quoin operational participated briefly to our million. that
clinical its of which strongest for including is ever raise, runway this key well half we orphan points development product have several As the addition strong a financial beyond also advance Quoin's our extends disease Furthermore, pipeline, to studies. and in successful that of XXXX, of in cash now cash to and our data is opportunities believe us capital support enable clinical space. company, of release position to pursue second this a we the plans from the at the our attractive M&A ongoing position rare inflection result will the into that
being no on tell we of in to exploring derisk forward assets. the of interested appropriate deal I this on updates particularly look at assurances can front our are progress acquiring executed, you late-stage can We interesting opportunities. be the a We while further that potentially time. number And there providing actively are
submission application, for of Syndrome. a QRXXXX of the Netherton XXXX highlight IND, for the key FDA U.S. was or as Investigational potential for in Drug New Quoin to One an the development treatment
we patients As result clinical of that of Netherton X opening studies in the subsequently IND, last a initiated year. successful
dividends as submission. letter, or and believe a our response manufacturers, on finished contract itself. made active and closely from ultimately product this We concentrated the of in to the scale-up substantial CMC-related regulatory early a QRXXXX complete CMOs, of a both FDA the operational deficiencies will in working by on Quoin well CMC-related and result that with progress very We matters the side also the of focus for as advance pay receiving reduce CRL, risk as the our development ingredient
diligently to actively Europe, prepared we on and stated, work throughout To we obtained. rollout working those previously to X approval establish once plans, territories product augment self-commercialize Quoin the successful been a fully we those QRXXXX U.S. plans outside we ensure has the infrastructure our territories. a of all and As in broad-based successfully of intends both the to in indeed other will and products those are that year have pipeline of be and for commercial
As is plan commercial of of established achieve of these countries global commercial distribution irrespective enable in that essentially of This infrastructure and our combination where XX the cover be feature group key those is products. to the differentiating that the is different partnerships alone. our U.S. primarily indicative have countries products launch key will partnerships who Quoin our result establish we world. a something is which X market made and and QRXXXX will to we the them in to tends located. now on pipeline that Europe, of are a for patient all be that needs also the to we focus efforts, of among It a the what our of The where U.S. the the ensuring is peer rest commitment available for they our believe effectively product every to company
quarter to the now itself. Turning fourth
announced being agreement and we X placebo and our trial test is over double-blinded were FDA, in daily Netherton QRXXXX the materials topical testing. the tested have first to to randomized applied are the X vehicle quarter, lotion X dosed. being patients. with in X the Recall versus different predesignated the once fully areas patient's opened Syndrome XX the of XX-week further of sites additional a period planned and The a study. are a by lotion are end quarter for body then, points operationally of vehicle ready in Europe intend the make and with of study pivotal clinical During progress initiate and end Furthermore, patient to control conduct patients. in potentially enrollment regulatory patient our since a that portion obtain clinical U.S. single doses first will approval. the that to assessed serve study as we This to study. in we the different of of the control study recruitment was Netherton continued this that And dosing
QRXXXX tested noted, approval As of commercial for a sufficient the the at that U.S. be total dose may indicated has previously in XX FDA the approximately with patients
based number sufficient and may obtain similar Europe. received we previously approval the be believe to constructive positive to a addition, In enable feedback regulatory us also in from on EMA, we the
trials During using once duration conducted a to also evaluate primarily therapy, will the the The savings. systemic second and be other study also off-label study the not Quoin's subjects the all patients. of is placebo-controlled an is endpoints a to of which clinical Syndrome approximately same and other ongoing resulting who under being is of a will to clinical as trial continue and investigators, cost assessed. in This efficiency trial with and with receiving X% and on study will currently trial the in degree daily clinical of be QRXXXX second open-label XX-week QRXXXX, X systemic XX ongoing we dose the predesignated our every the the over body same a same operational open our tested quarter, initiation day biologics. receive period. This announced concurrently is Netherton clinical study IND running applied are throughout site trial sites patients are high This design in same is being and
providing as studies interim partners of for data. that data we may be package or release early study, the both distribution course approval that our the a the is access including either regulatory the seek these sufficient of have believe inclusion respective for product number programs in to of their in data formal territories. anticipate several study, of to Given is We updates ongoing we open-label of will generated, it being during the potentially an access this and the
a with accordingly. is and in defined We which working granted formal regulatory marketing for no a the Europe requirements medical believe commercialization EMA may to certainly are need Syndrome circumstances better Netherton also with of allows the are QRXXXX the conditional we working regulatory the where this that particular approval for by in We prepare can there to consultants approval. and where clearly available understand marketing case product and a advance medical timing treatment approval determine our if application Conditional that is in so qualify for we is of exists. disease
continue outreach quarter, once an as helped of communication the the of build at into ongoing of vital our network have early for to channels family clinical approved. believe and our to broadly progress of of has believe events the that engagement data. release our launch the large, update distributed integration we These clinical understanding the our of will programs. key our disease We our awareness of to a foundation be and a establish that Netherton of successful to deepen helps network a and this community the with treating members, engagement such product relationships anticipated timing regular facilitate We and to members supporting also foundations. Quoin strengthening community that of Throughout level physicians and been patients, in community this critical
has Turning projects continue the of our good by scientists feedback could year. both dollars testing Queensland initiate at Technology to are Australia, the Australia, the rebate spent in all cost-effective to is rendering performed including XX.X% offered of Australian incentives varying of this a for highly programs the research perhaps QUT, we clinical hopeful end based testing make government at now that This been Quoin. able Quoin take from progress. on by to initial research project QUT, of or one where generous both And advantage programs these University or in the of
these relatively products disease at everybody important still on early While of progress. as their we components portfolio, view updated of forward development, and rare we look a to keeping our stage
quarter let on update turn discuss that me fourth our results. With to our operational over this Gordon progress, to financial
